Cargando…
Effectiveness of methotrexate as a second-line treatment for cardiac sarcoidosis assessed via (18)F-FDG PET: a case report
BACKGROUND: Although methotrexate has been widely used as a second-line therapy for cardiac sarcoidosis (CS), it is not clear if it has a direct anti-inflammatory effect. CASE SUMMARY: A 65-year-old man presented to our hospital with symptomatic ventricular tachycardia (VT). After cardioversion, ele...
Autores principales: | Dotare, Taishi, Maeda, Daichi, Matsue, Yuya, Minamino, Tohru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195226/ https://www.ncbi.nlm.nih.gov/pubmed/35712221 http://dx.doi.org/10.1093/ehjcr/ytac226 |
Ejemplares similares
-
The Prognostic Value of B‐Type Natriuretic Peptide in Patients With Cardiac Sarcoidosis Without Heart Failure: Insights From ILLUMINATE‐CS
por: Miyakuni, Shota, et al.
Publicado: (2022) -
Prevalence and prognostic value of atrial fibrillation in patients with cardiac sarcoidosis
por: Fujimoto, Yudai, et al.
Publicado: (2023) -
(18)F-FDG-PET of cardiac sarcoidosis with subcutaneous nodules
por: Sillanmäki, Saara, et al.
Publicado: (2023) -
Scar Sarcoidosis on (18)F-FDG PET/CT
por: Arora, Saurabh, et al.
Publicado: (2019) -
Urinary liver‐type fatty acid‐binding protein as a prognostic marker in patients with acute heart failure
por: Sunayama, Tsutomu, et al.
Publicado: (2021)